BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Beta Bionics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$16.84+0.49 (+3.00%)
Close on Oct 19, 2026
- Market cap
- $750.14M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
48M of 45M shares
Institutional holders
134
30 new, 23 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
0 buys · 52 sales
Net sold $5.38M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 8,943,061 | 16.60% | 13G (passive) | Sep 30, 2026 |
| Eventide Asset Management, LLC | 5,945,488 | 13.40% | 13G (passive) amendment | Mar 31, 2026 |
| Finny Kuruvilla, M.D., Ph. D. | 4,857,041 | 11.32% | 13G (passive) | Jan 31, 2025 |
| Warren, John R. | 4,379,920 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Levy Guy | 4,354,501 | 9.80% | 13G (passive) amendment | Mar 31, 2026 |
| Patel, Rajiv A. | 4,313,920 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Gehani, Varun N. | 4,203,920 | 9.70% | 13G (passive) amendment | Jun 30, 2025 |
| Wellington Management Group LLP | 3,901,599 | 9.00% | 13G (passive) | Mar 31, 2025 |
| Soleus GP, LLC | 3,795,341 | 8.80% | 13G (passive) | Mar 31, 2025 |
| Morgan Stanley | 3,739,567 | 8.60% | 13G (passive) amendment | Sep 30, 2025 |
| Dreyfuss, Philip D. | 3,607,920 | 8.10% | 13G (passive) amendment | Mar 31, 2026 |
| Sands Capital Life Sciences Pulse Fund II. L.P. | 3,570,113 | 8.20% | 13G (passive) amendment | Jun 30, 2025 |
| Luo Patrick (Cheng) | 3,427,220 | 7.90% | 13G (passive) | Jan 31, 2025 |
| Roderick Wong, M.D. | 3,299,869 | 7.60% | 13G (passive) | Mar 31, 2025 |
| Frank M. Sands | 3,154,409 | 7.30% | 13G (passive) | Apr 2, 2025 |
| Divisadero Street Capital Management, LP | 3,072,985 | 6.90% | 13G (passive) | Jul 17, 2026 |
| BlackRock, Inc. | 2,778,764 | 6.40% | 13G (passive) | Sep 30, 2025 |
| Guy Levy | 2,534,565 | 5.80% | 13G (passive) amendment | Dec 31, 2025 |
| RTW Investments, LP | 2,500,000 | 5.70% | 13G (passive) amendment | Dec 31, 2025 |
| Point72 Asset Management, L.P. | 2,290,023 | 5.20% | 13G (passive) | Feb 18, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BBNX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Eventide Asset Management, LLC | 6,253,673 | 13.90% | $98.05M | +308,185 | 1.31% |
| Soleus Capital Management, L.P. | 4,393,714 | 9.77% | $68.85M | +39,213 | 2.37% |
| Morgan Stanley | 4,266,822 | 9.48% | $66.86M | +39,188 | 0.00% |
| Sands Capital Ventures, LLC | 3,708,043 | 8.24% | $58.11M | – | 9.47% |
| BlackRock, Inc. | 3,340,171 | 7.42% | $52.34M | +301,576 | 0.00% |
| Point72 Asset Management, L.P. | 2,254,683 | 5.01% | $35.33M | −270,357 | 0.04% |
| Vanguard Capital Management LLC | 1,782,346 | 3.96% | $27.93M | +54,369 | 0.00% |
| Vestal Point Capital, LP | 1,600,000 | 3.56% | $25.07M | −611,518 | 0.59% |
| Rtw Investments, LP | 1,500,000 | 3.33% | $23.51M | −500,000 | 0.20% |
| Deerfield Management Company, L.P. (Series C) | 1,324,000 | 2.94% | $20.75M | – | 0.22% |
| Omega Fund Management, LLC | 1,316,183 | 2.93% | $20.62M | – | 11.11% |
| Eversept Partners, LP | 1,249,441 | 2.78% | $19.58M | −165,397 | 1.02% |
| Divisadero Street Capital Management, LP | 1,113,802 | 2.48% | $17.45M | New | 0.40% |
| Geode Capital Management, LLC | 1,073,452 | 2.39% | $16.82M | +140,774 | 0.00% |
| State Street Corp | 970,192 | 2.16% | $15.20M | +24,105 | 0.00% |
| Millennium Management LLC | 956,244 | 2.13% | $14.98M | +95,378 | 0.01% |
| Balyasny Asset Management L.P. | 855,682 | 1.90% | $13.41M | +237,767 | 0.02% |
| Perceptive Advisors LLC | 832,944 | 1.85% | $13.05M | −10,000 | 0.20% |
| JPMorgan Chase & Co | 703,356 | 1.56% | $11.96M | +396,127 | 0.00% |
| Bruce & Co., Inc. | 665,700 | 1.48% | $10.43M | +115,000 | 2.82% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 134 | 48M | 100.0% | 30 / 56 | 35 / 23 | 6M | 7M |
| Q1 2026 | 130 | 49M | 100.0% | 24 / 47 | 47 / 47 | 14M | 10M |
| Q4 2025 | 158 | 47M | 100.0% | 46 / 60 | 31 / 16 | 8M | 9M |
| Q3 2025 | 129 | 49M | 100.0% | 29 / 58 | 21 / 16 | 10M | 6M |
| Q2 2025 | 116 | 45M | 99.7% | 28 / 38 | 27 / 13 | 7M | 4M |
| Q1 2025 | 102 | 42M | 92.7% | 102 / 0 | 0 / 0 | 42M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BBNX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Eventide Gilead Fund | 3,983,917 | 8.86% | $62.43M | 1.81% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 2,052,176 | 4.56% | $32.16M | 1.80% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,272,504 | 2.83% | $19.94M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,062,586 | 2.36% | $16.65M | 0.02% | Jun 30, 2026 |
| Bruce Fund | 665,700 | 1.48% | $10.43M | 2.78% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 469,615 | 1.04% | $7.36M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 445,440 | 0.99% | $5.71M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 378,433 | 0.84% | $5.93M | 0.04% | Jun 30, 2026 |
| JPMorgan Small Cap Value Fund | 221,450 | 0.49% | $3.47M | 0.26% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 208,920 | 0.46% | $2.53M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 200,344 | 0.45% | $2.43M | 0.01% | May 31, 2026 |
| iShares U.S. Medical Devices ETF | 189,897 | 0.42% | $2.98M | 0.10% | Jun 30, 2026 |
| Schwab U.S. Small-Cap ETF | 188,948 | 0.42% | $2.29M | 0.01% | May 31, 2026 |
| Eventide Exponential Technologies Fund | 173,298 | 0.39% | $2.72M | 2.57% | Jun 30, 2026 |
| JPMorgan U.S. Small Company Fund | 126,797 | 0.28% | $1.99M | 0.18% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sean Saint | President & CEO, Director | 398,429 | 0.89% | Sep 4, 2026 |
| Mark Hopman | Chief Commercial Officer | 88,033 | 0.20% | Sep 18, 2026 |
| Mike Mensinger | Chief Product Officer | 177,390 | 0.39% | Sep 17, 2026 |
| Steven Jon Russell | Chief Medical Officer | 207,699 | 0.46% | Sep 3, 2026 |
| Stephen Feider | Chief Financial Officer | 159,378 | 0.35% | Sep 3, 2026 |
| Christy Jones | Director | 19,564 | 0.04% | Sep 23, 2026 |
| Danny L. Dearen | Director | 32,209 | 0.07% | May 26, 2026 |
| Sean Carney | Director | 32,209 | 0.07% | May 26, 2026 |
| Gerard J. Michel | Director | 33,509 | 0.07% | May 26, 2026 |
| Maria Palasis | Director | 29,397 | 0.07% | May 26, 2026 |
| Adam Lezack | Director | 27,399 | 0.06% | May 26, 2026 |
| Wellington Hadley Harbor Aggregator IV, L.P. | 10% owner | 3,901,599 | 8.67% | Feb 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Christy Jones Director | Sep 22, 2026 | Sale(10b5-1 plan) | −6,430 | $23.00 | $147.89K | 19,564 |
| Mark Hopman Chief Commercial Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −30,779 | $20.13 | $619.58K | 56,479 |
| Mike Mensinger Chief Product Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −2,650 | $22.00 | $58.30K | 177,390 |
| Mark Hopman Chief Commercial Officer | Sep 14, 2026 | Sale(10b5-1 plan) | −775 | $15.52 | $12.03K | 86,382 |
| Mark Hopman Chief Commercial Officer | Sep 9, 2026 | Sale(10b5-1 plan) | −35,994 | $18.46 | $664.45K | 88,033 |
| Mark Hopman Chief Commercial Officer | Sep 9, 2026 | Sale(10b5-1 plan) | −36,870 | $18.46 | $680.62K | 87,157 |
| Sean Saint President & CEO, Director | Sep 3, 2026 | Sale(10b5-1 plan) | −5,641 | $20.08 | $113.27K | 398,429 |
| Mark Hopman Chief Commercial Officer | Sep 2, 2026 | Sale | −5,327 | $19.11 | $101.80K | 124,027 |
| Sean Saint President & CEO, Director | Sep 2, 2026 | Sale | −16,867 | $19.11 | $322.33K | 404,070 |
| Stephen Feider Chief Financial Officer | Sep 2, 2026 | Sale | −6,675 | $19.11 | $127.56K | 159,378 |
| Mike Mensinger Chief Product Officer | Sep 2, 2026 | Sale | −4,375 | $19.11 | $83.61K | 180,040 |
| Steven Jon Russell Chief Medical Officer | Sep 2, 2026 | Sale | −4,221 | $19.11 | $80.66K | 169,628 |
| Stephen Feider Chief Financial Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −4,896 | $17.03 | $83.38K | 166,053 |
| Stephen Feider Chief Financial Officer | Jun 29, 2026 | Option exercise | +4,896 | $5.10 | $24.97K | 170,949 |
| Stephen Feider Chief Financial Officer | Jun 29, 2026 | Option exercise | +4,896 | $5.10 | $24.97K | 170,827 |
| Stephen Feider Chief Financial Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −4,896 | $17.03 | $83.38K | 165,931 |
| Stephen Feider Chief Financial Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −5,104 | $17.05 | $87.02K | 166,053 |
| Stephen Feider Chief Financial Officer | Jun 26, 2026 | Option exercise | +5,104 | $5.10 | $26.03K | 171,157 |
| Stephen Feider Chief Financial Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −5,104 | $17.05 | $87.02K | 165,931 |
| Stephen Feider Chief Financial Officer | Jun 26, 2026 | Option exercise | +4,982 | $5.10 | $25.41K | 171,035 |
| Mark Hopman Chief Commercial Officer | Jun 24, 2026 | Sale(10b5-1 plan) | −1,258 | $15.01 | $18.88K | 129,354 |
| Christy Jones Director | Jun 24, 2026 | Sale(10b5-1 plan) | −1,406 | $15.00 | $21.09K | 25,994 |
| Christy Jones Director | Jun 4, 2026 | Sale(10b5-1 plan) | −2,811 | $14.00 | $39.35K | 27,400 |
| Mark Hopman Chief Commercial Officer | Jun 4, 2026 | Sale(10b5-1 plan) | −275 | $12.31 | $3.39K | 130,612 |
| Steven Jon Russell Chief Medical Officer | Jun 2, 2026 | Sale | −4,222 | $12.61 | $53.24K | 173,849 |
| Stephen Feider Chief Financial Officer | Jun 2, 2026 | Sale | −6,676 | $12.61 | $84.18K | 166,053 |
| Sean Saint President & CEO, Director | Jun 2, 2026 | Sale | −16,872 | $12.61 | $212.76K | 420,937 |
| Mark Hopman Chief Commercial Officer | Jun 2, 2026 | Sale | −5,329 | $12.61 | $67.20K | 130,887 |
| Mike Mensinger Chief Product Officer | Jun 2, 2026 | Sale | −4,378 | $12.61 | $55.21K | 184,415 |
| Adam Lezack Director | May 22, 2026 | Sale(10b5-1 plan) | −998 | $11.21 | $11.19K | 27,399 |
| Danny L. Dearen Director | May 21, 2026 | Award | +16,965 | – | – | 32,209 |
| Christy Jones Director | May 21, 2026 | Award | +16,965 | – | – | 30,211 |
| Christy Jones Director | May 21, 2026 | Sale(10b5-1 plan) | −1,998 | $9.95 | $19.88K | 13,246 |
| Maria Palasis Director | May 21, 2026 | Award | +16,965 | – | – | 29,397 |
| Adam Lezack Director | May 21, 2026 | Award | +16,965 | – | – | 28,397 |
| Adam Lezack Director | May 21, 2026 | Sale(10b5-1 plan) | −1,000 | $9.95 | $9.95K | 11,432 |
| Sean Carney Director | May 21, 2026 | Award | +16,965 | – | – | 32,209 |
| Gerard J. Michel Director | May 21, 2026 | Award | +16,965 | – | – | 33,509 |
| Mark Hopman Chief Commercial Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −353 | $11.57 | $4.08K | 139,133 |
| Mike Mensinger Chief Product Officer | Mar 2, 2026 | Sale | −1,064 | $12.36 | $13.15K | 188,793 |
| Mark Hopman Chief Commercial Officer | Mar 2, 2026 | Sale | −834 | $12.36 | $10.31K | 139,486 |
| Stephen Feider Chief Financial Officer | Mar 2, 2026 | Sale | −1,428 | $12.36 | $17.65K | 172,729 |
| Steven Jon Russell Chief Medical Officer | Mar 2, 2026 | Sale | −1,026 | $12.36 | $12.68K | 179,096 |
| Sean Saint President & CEO, Director | Mar 2, 2026 | Sale | −3,384 | $12.36 | $41.83K | 437,809 |
| Mike Mensinger Chief Product Officer | Feb 27, 2026 | Award | +109,105 | – | – | 189,857 |
| Mark Hopman Chief Commercial Officer | Feb 27, 2026 | Award | +109,105 | – | – | 140,320 |
| Stephen Feider Chief Financial Officer | Feb 27, 2026 | Award | +131,543 | – | – | 174,157 |
| Steven Jon Russell Chief Medical Officer | Feb 27, 2026 | Award | +109,105 | – | – | 180,122 |
| Sean Saint President & CEO, Director | Feb 27, 2026 | Award | +343,269 | – | – | 441,193 |
| Gerard J. Michel Director | Jan 13, 2026 | Award | +3,997 | – | – | 16,544 |
| Maria Palasis Director | Jan 13, 2026 | Award | +3,997 | – | – | 12,432 |
| Christy Jones Director | Jan 13, 2026 | Award | +3,997 | – | – | 15,244 |
| Adam Lezack Director | Jan 13, 2026 | Award | +3,997 | – | – | 12,432 |
| Sean Carney Director | Jan 13, 2026 | Award | +3,997 | – | – | 15,244 |
| Danny L. Dearen Director | Jan 13, 2026 | Award | +3,997 | – | – | 15,244 |
| Mike Mensinger Chief Product Officer | Jan 6, 2026 | Sale(10b5-1 plan) | −2,200 | $30.10 | $66.22K | 80,752 |
| Mike Mensinger Chief Product Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −600 | $30.20 | $18.12K | 82,952 |
| Mike Mensinger Chief Product Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −7,200 | $29.56 | $212.83K | 83,552 |
| Stephen Feider Chief Financial Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −20,000 | $29.53 | $590.60K | 42,614 |
| Stephen Feider Chief Financial Officer | Jan 2, 2026 | Option exercise | +20,000 | $5.10 | $102.00K | 62,614 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Hopman Mark Officer | Oct 1, 2026 | 2,660 | $50.49K | Oct 1, 2026 | Exercise of Stock Options |
| Jones Christina Director | Sep 22, 2026 | 8,942 | $197.08K | Sep 22, 2026 | Exercise of Stock Options |
| Mensinger Michael Officer | Sep 16, 2026 | 5,300 | $101.92K | Sep 16, 2026 | Series D Purchase |
| Hopman Mark Officer | Sep 16, 2026 | 28,119 | $540.73K | Sep 16, 2026 | Exercise of Stock Options |
| Hopman Mark Officer | Sep 9, 2026 | 40,305 | $779.10K | Sep 9, 2026 | Exercise of Stock Options |
| Feider Stephen Officer | Sep 3, 2026 | 6,675 | $129.60K | Sep 2, 2026 | Restricted Stock Units vesting under registered plan |
| R. Mensinger Michael Officer | Sep 3, 2026 | 4,375 | $84.94K | Sep 2, 2026 | Restricted Stock Units vesting under registered plan |
| Jon Russell Steven Officer | Sep 3, 2026 | 4,221 | $81.95K | Sep 2, 2026 | Restricted Stock Units vesting under registered plan |
| Hopman Mark Officer | Sep 3, 2026 | 5,327 | $103.42K | Sep 2, 2026 | Restricted Stock Units vesting under registered plan |
| Saint Sean Officer | Sep 3, 2026 | 5,641 | $113.26K | Sep 3, 2026 | Equity Award |
| Saint Sean Officer, Director | Sep 3, 2026 | 16,867 | $327.47K | Sep 2, 2026 | Restricted Stock Units vesting under registered plan |
| Feider Stephen Officer | Jun 29, 2026 | 4,896 | $83.38K | Jun 29, 2026 | Stock Options |
| Feider Stephen Officer | Jun 26, 2026 | 5,104 | $87.01K | Jun 26, 2026 | Stock Options |
| Hopman Mark Officer | Jun 24, 2026 | 1,258 | $18.83K | Jun 24, 2026 | Equity Award |
| Jones Christina Director | Jun 24, 2026 | 1,406 | $19.22K | Jun 24, 2026 | Restricted Stock Units |